Contracts › 75F40124C00013

75F40124C00013: The Goal of This Project Is to Develop an Objective, Quantitative, and User-Friendly Digital Endpoint to Assess Nocturnal Scratching in Children With Atopic Dermatitis. This Endpoint Will Fulfill a Crucial Unmet Need By for Assessing the Efficacy

Awarded to Emerald Innovations, Inc. by Food and Drug Administration (FDA).

$2.0Mobligated

$2.0Mpotential value

29 May 2028current end date

See modifications, all subcontractors and funding in FedSift →

Contract	75F40124C00013
Awardee	Emerald Innovations, Inc.
Awarding agency	Food and Drug Administration (FDA)
Awarding office	FDA OFFICE OF ACQ GRANT SVCS
NAICS	541714 Research and Development in Biotechnology (Except Nanobiotechnology)
PSC	B504 Special Studies/Analysis- Chemical/Biological
Place of performance	MA
Offers received	1
Period of performance	06 December 2023 to 29 May 2028
Potential end	29 May 2028
Estimated recompete solicitation	~Q4 2027 (estimate, ~6 months before expiry)

Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.